Insurance: insurers; coverage for certain pediatric autoimmune neuropsychiatric disorders; require. Amends 1956 PA 218 (MCL 500.100 - 500.8302) by adding sec. 3406pp.
Summary
Senate Bill 447 would amend Michigan’s Insurance Code to require health insurance policies to cover the prophylaxis, diagnosis, and treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS). The required coverage would include a broad range of physician-ordered services and therapies, such as antibiotics, medications, behavioral therapies, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin therapy.
The bill also sets coverage standards intended to make access more uniform and timely. It prohibits insurers from imposing higher copayments, deductibles, or coinsurance for these services than for other covered benefits, requires timely authorization for urgent treatment, bars denial or delay based on prior treatment history or a different diagnostic label, and prevents insurers from requiring a step-therapy approach limited to symptom-only treatments before approving immunomodulating therapies. It further directs insurers and the Department of Insurance and Financial Services to rely on treatment recommendations from a medical professional consortium and to use specified diagnostic coding rules for billing purposes.
Impact
If enacted, the bill would add a new mandated-benefit section to the Michigan Insurance Code and apply it to existing and future health insurance policies, including out-of-state policies covering Michigan residents, beginning 90 days after enactment. Insurers would have to cover PANDAS/PANS-related care under the same cost-sharing terms as other benefits, follow the bill’s authorization and coverage standards, and recognize the specified diagnosis/coding framework unless and until national coding authorities create a specific code. The measure would primarily affect health insurers, providers, and families seeking treatment for these pediatric neuropsychiatric conditions.
Sentiment
Based on the bill text and the absence of recorded committee testimony or votes in the provided materials, the bill appears to be framed as a patient-access measure with a strong pro-coverage orientation. Its structure suggests support for families and clinicians who believe these conditions require specialized treatment and insurance recognition. No opposing arguments are documented in the provided context, but the bill’s detailed coverage mandates indicate it is designed to address perceived insurer barriers to care.
Contention
The main points of potential contention are likely to be medical necessity, evidence standards, and insurer utilization management. The bill requires insurers to defer to treatment recommendations from a medical professional consortium and limits the ability to require step therapy or deny care based on prior diagnoses or alternative diagnostic names such as autoimmune encephalopathy. Insurers may view these provisions as restricting their ability to apply standard coverage review or evidence-based medical management, while supporters would likely argue that the bill prevents inappropriate denials and delays for children with PANDAS/PANS.